Artificial intelligence and amikacin exposures predictive of outcomes in multidrug-resistant tuberculosis patients

Chawangwa Modongo, Jotam G. Pasipanodya, Beki T. Magazi, Shashikant Srivastava, Nicola M. Zetola, Scott M. Williams, Giorgio Sirugo, Tawanda Gumbo

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Aminoglycosides such as amikacin continue to be part of the backbone of treatment of multidrug-resistant tuberculosis (MDRTB). We measured amikacin concentrations in 28 MDR-TB patients in Botswana receiving amikacin therapy together with oral levofloxacin, ethionamide, cycloserine, and pyrazinamide and calculated areas under the concentration-time curves from 0 to 24 h (AUC024). The patients were followed monthly for sputum culture conversion based on liquid cultures. The median duration of amikacin therapy was 184 (range, 28 to 866) days, at a median dose of 17.30 (range 11.11 to 19.23) mg/kg. Only 11 (39%) patients had sputum culture conversion during treatment; the rest failed. We utilized classification and regression tree analyses (CART) to examine all potential predictors of failure, including clinical and demographic features, comorbidities, and amikacin peak concentrations (Cmax), AUC024, and trough concentrations. The primary node for failure had two competing variables, Cmax of67 mg/liter and AUC024 of<568.30 mg • h/L; weight of>41 kg was a secondary node with a score of 35% relative to the primary node. The area under the receiver operating characteristic curve for the CART model was an R2=0.90 on posttest. In patients weighing 41 kg, sputum conversion was 3/3 (100%) in those with an amikacin Cmax of 67 mg/liter versus 3/15 (20%) in those with a Cmax of<67 mg/liter (relative risk [RR]=5.00; 95% confidence interval [CI], 1.82 to 13.76). In all patients who had both amikacin Cmax and AUC024 below the threshold, 7/7 (100%) failed, compared to 7/15 (47%) of those who had these parameters above threshold (RR=2.14; 95% CI, 1.25 to 43.68). These amikacin dose-schedule patterns and exposures are virtually the same as those identified in the hollow-fiber system model.

Original languageEnglish (US)
Pages (from-to)5928-5932
Number of pages5
JournalAntimicrobial agents and chemotherapy
Issue number10
StatePublished - Oct 2016
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Artificial intelligence and amikacin exposures predictive of outcomes in multidrug-resistant tuberculosis patients'. Together they form a unique fingerprint.

Cite this